Literature DB >> 23998966

Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD).

S Fütterer1, I Andrusenko, U Kolb, W Hofmeister, P Langguth.   

Abstract

Drug products containing iron oxide and hydroxide nanoparticles (INPs) are important for the treatment of iron deficiency anaemia. Pharmaceuticals prepared by the complexation of different kinds of INPs and carbohydrates have different physicochemical and biopharmaceutic characteristics. The increasing number of parenteral non-biological complex drugs (NBCD) containing iron requires physicochemical methods for characterization and enabling of cross comparisons. In this context the structure and the level of crystallinity of the iron phases may be connected to the in vitro and in vivo dissolution rates, which etiologically determine the therapeutic and toxic effects. X-ray powder diffraction (XRPD) and electron diffraction (ED) methods were used in order to investigate the nine different parenteral iron formulations Ferumoxytol (Feraheme(®)), sodium ferric gluconate sucrose (Ferrlecit(®)), iron sucrose (Venofer(®)), low molecular weight iron dextran (CosmoFer(®)), low molecular weight iron dextran (Infed(®)), high molecular weight iron dextran (Ironate(®)), high molecular weight iron dextran (Dexferrum(®)), iron carboxymaltose (Ferinject(®)) and iron isomaltoside 1000 (Monofer(®)). The iron phase in CosmoFer(®), Ferinject(®), Monofer(®), Infed(®), Ironate(®) and Dexferrum(®) was identified as Akaganéite/Akaganéite-like (β-FeOOH), with low amounts of chloride. By combining results of both methods the iron oxide in Feraheme(®) was identified as Magnetite (Fe3O4) with spinel-like structure. Ferrlecit(®) and Venofer(®) were difficult to analyze due to the low degree of crystallinity, but the iron phase seems to fit Lepidocrocite/Lepidocrocite-like (γ-FeOOH) or an amorphous kind of structure. The structural information on the type of iron oxide or hydroxide together with the particle size allows predicting the stability of the different complexes including their labile iron content. The combination of ED and XRPD methods is a very helpful approach especially for structural analysis of nanoscopic or low crystalline materials.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Free iron; Labile iron; Non-biological complex drugs; Stability; Structure

Mesh:

Substances:

Year:  2013        PMID: 23998966     DOI: 10.1016/j.jpba.2013.08.005

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  19 in total

Review 1.  The Labile Side of Iron Supplementation in CKD.

Authors:  Itzchak Slotki; Zvi Ioav Cabantchik
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

Review 2.  Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain.

Authors:  Liron L Israel; Anna Galstyan; Eggehard Holler; Julia Y Ljubimova
Journal:  J Control Release       Date:  2020-01-07       Impact factor: 9.776

3.  Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues.

Authors:  Saeid Zanganeh; Gregor Hutter; Ryan Spitler; Olga Lenkov; Morteza Mahmoudi; Aubie Shaw; Jukka Sakari Pajarinen; Hossein Nejadnik; Stuart Goodman; Michael Moseley; Lisa Marie Coussens; Heike Elisabeth Daldrup-Link
Journal:  Nat Nanotechnol       Date:  2016-09-26       Impact factor: 39.213

4.  Heat-induced radiolabeling and fluorescence labeling of Feraheme nanoparticles for PET/SPECT imaging and flow cytometry.

Authors:  Hushan Yuan; Moses Q Wilks; Marc D Normandin; Georges El Fakhri; Charalambos Kaittanis; Lee Josephson
Journal:  Nat Protoc       Date:  2018-01-25       Impact factor: 13.491

Review 5.  Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management.

Authors:  J Szebeni; S Fishbane; M Hedenus; S Howaldt; F Locatelli; S Patni; D Rampton; G Weiss; J Folkersen
Journal:  Br J Pharmacol       Date:  2015-10-25       Impact factor: 8.739

Review 6.  Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.

Authors:  Peng Zou; Katherine Tyner; Andre Raw; Sau Lee
Journal:  AAPS J       Date:  2017-07-31       Impact factor: 4.009

7.  Can the biomolecular corona induce an allergic reaction?-A proof-of-concept study.

Authors:  Anne Muehe; Hossein Nejadnik; Henrik Muehe; Jarrett Rosenberg; Hassan Gharibi; Amir Ata Saei; Shu-Chen Lyu; Kari C Nadeau; Morteza Mahmoudi; Heike E Daldrup-Link
Journal:  Biointerphases       Date:  2021-02-03       Impact factor: 2.456

8.  Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate.

Authors:  Joel E P Brandis; Kyle C Kihn; Marc B Taraban; Julia Schnorr; Alex M Confer; Sharon Batelu; Dajun Sun; Jason D Rodriguez; Wenlei Jiang; David P Goldberg; Peter Langguth; Timothy L Stemmler; Yihua Bruce Yu; Maureen A Kane; James E Polli; Sarah L J Michel
Journal:  Mol Pharm       Date:  2021-02-23       Impact factor: 5.364

9.  Poly(ethylene glycol)-Alendronate-Coated Magnetite Nanoparticles Do Not Alter Cardiovascular Functions and Red Blood Cells' Properties in Hypertensive Rats.

Authors:  Viktoriia Oleksa; Iveta Bernátová; Vitalii Patsula; Silvia Líšková; Peter Bališ; Jana Radošinská; Andrea Mičurová; Michal Kluknavský; Tomáš Jasenovec; Dominika Radošinská; Hana Macková; Daniel Horák
Journal:  Nanomaterials (Basel)       Date:  2021-05-07       Impact factor: 5.076

10.  Distinct immunologic effects of different intravenous iron preparations on monocytes.

Authors:  Lisa H Fell; Adam M Zawada; Kyrill S Rogacev; Sarah Seiler; Danilo Fliser; Gunnar H Heine
Journal:  Nephrol Dial Transplant       Date:  2014-02-11       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.